Chinook Therapeutics Inc expected to post a loss of 67  cents a share - Earnings Preview

Chinook Therapeutics

06/05/2022 18:02

* Chinook Therapeutics Inc  KDNY.OQ   KDNY.O  is expected
to show
a fall in quarterly revenue when it reports  results on May 10
(estimated). 
    * ​Refinitiv's mean analyst estimate for Chinook
Therapeutics Inc
is for a loss of 67 cents per share. For the same quarter last
year, the company reported a loss of 88 cents per share.
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 8 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Chinook
Therapeutics Inc is $29​, above​ its last closing price
of $14.02. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.75       -0.68      0.14      Beat    120.7
 Sep. 30 2021  -0.88       -0.84      -0.69     Beat    17.7
 Jun. 30 2021  -0.79       -0.78      -1.14     Missed  -45.5​
 Mar. 31 2021  -0.65       -0.68      -0.88     Missed  -30
 ​​Dec.        -0.51       -0.44      -1.24     Missed  -178.7
 31 2020                                                
 Sep. 30 2020  -0.49       -0.45      -0.90     Missed  -97.8​
 Jun. 30 2020  -1.01       -0.95      -1.05     Missed  -10.5
 Mar. 31 2020  -0.76       -0.67      -0.45     Beat    33.3
 This summary was machine generated May 6 at 17:02 GMT.  All
figures in US dollars  unless otherwise stated